mircera
roche registration gmbh - metoxi-polietilenglicol epoetina beta - anemia; kidney failure, chronic - preparaciones antianémicas - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.
mircera 100mcg/0.3ml solución inyectable
roche farma (peru) s.a. - metoxipolietilenglicol - epoetina beta - solución inyectable - 100mcg/0.3ml - por jeringa prellenada ml; metoxipolietilenglicol-epoetina beta 100.000000 mg; - metoxipolietilenglicol-epoetina beta
mircera solución inyectable 150 mcg/0,3 ml (metoxipolietilenglicol-epoetina beta)
roche chile ltda. - metoxipolietilenglicol-epoetina beta - sin formulas
mircera 50mcg/0.3ml solucion inyectable
roche farma (peru) s.a. - metoxipolietilenglicol-epoetina beta; - solucion inyectable - por jeringa prellenada ml; metoxipolietilenglicol-epoetina beta 0.050000 mg; - metoxipolietilenglicol-epoetina beta
mircera
f. hoffmann-la roche s.a., basilea, suiza. - metoxipolietilenglicol epoetina beta -
mircera
f. hoffmann-la roche s.a., basilea, suiza. - metoxipolietilenglicol epoetina beta -
mircera
f. hoffmann-la roche s.a., basilea, suiza. - metoxipolietilenglicol epoetina beta -
mircera
f. hoffmann-la roche s.a., basilea, suiza. - metoxipolietilenglicol epoetina beta -
mircera solución inyectable 100 mcg/0,3 ml
roche chile ltda. - metoxipolietilenglicol-epoetina beta - sin formulas
nominee®
bayer ag -